Section Arrow
TVTX.NASDAQ
- Travere Therapeutics
Quotes are at least 15-min delayed:2026/01/08 06:17 EST
Pre Market
Last
 36.1
-0.18 (-0.50%)
Bid
36.39
Ask
37.49
High 37.5 
Low 36.1 
Volume 263 
Regular Hours (Closed)
Last
 36.28
+0.48 (+1.34%)
Day High 
37.45 
Prev. Close
35.8 
1-M High
42.13 
Volume 
2.68M 
Bid
36.39
Ask
37.49
Day Low
35.52 
Open
35.8 
1-M Low
33.49 
Market Cap 
3.20B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 38 
20-SMA 36.33 
50-SMA 34.93 
52-W High 42.13 
52-W Low 12.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.03/1.42
Enterprise Value
3.53B
Balance Sheet
Book Value Per Share
0.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
233.18M
Operating Revenue Per Share
2.59
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
Pre Market 0.1215 -0.0041 -3.26%
ERASErasca5.17+1.54+42.42%-- 
Pre Market 4.52 -0.65 -12.57%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
Pre Market 4.77 -0.09 -1.85%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
Pre Market 13.74 +0.01 +0.07%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
Pre Market 22.99 -0.29 -1.25%
Industry overview quotes are at least 15 minutes delayed
Business Description
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.